• https://icimice.unwahas.ac.id/image/wp-config/
  • http://ted.bti.cornell.edu/pepper/tmp/sgacor/
  • https://packmem.ipmc.cnrs.fr/img/files/
  • https://bid.cbf.com.br/product/borobudurbet/
  • https://cnrd.cbf.com.br/user/betshelter/
  • http://digilib.iaknambon.ac.id:8123/img/user/
  • https://bid.cbf.com.br/product/auroratoto/
  • This site is part of the Siconnects Division of Sciinov Group

    This site is operated by a business or businesses owned by Sciinov Group and all copyright resides with them.

    ADD THESE DATES TO YOUR E-DIARY OR GOOGLE CALENDAR

    Registration

    14 Dec
    2023

    26 Oct
    2023

    Pfizer and BioNTech Announce Positive Topline Data for mRNA-based Combination Vaccine Program Against Influenza and COVID-19

    Safety profile of the mRNA-based combination vaccine candidates consistent with the companies’ COVID-19 vaccineReadmore

    25 May
    2023

    Pfizer’s PAXLOVID™ Receives FDA Approval for Adult Patients at High Risk of Progression to Severe COVID-19

    PAXLOVID is the first FDA-approved oral treatment for COVID-19; has been authorized for emergency use since December 2021Readmore

    04 Apr
    2023

    InflaRx Receives FDA Emergency Use Authorization for Gohibic (vilobelimab) for Treatment of Critically Ill COVID-19 Patients

    Vilobelimab is the first authorized drug to control complement factor C5a, a protein that plays an important and often harmful role in the body´s immune responseReadmore

    Subscribe to our News & Updates